Source comparison
MOTS-c vs SLU-PP-332: Which Peptide Works Better?
A 2022 study published in Nature Communications found that MOTS-c administration increased skeletal muscle insulin sensitivity by 47% in aged mice without altering body weight—a metabolic improvement independent of caloric restriction. That same year, research
This comparison does not assign a generated winner or score.
- A 2022 study published in Nature Communications found that MOTS-c administration increased skeletal muscle insulin sensitivity by 47% in aged mice without altering body weight—a metabolic improvement independent of caloric restriction. That same year, researchers at Scripps identified SLU-PP-332 (often abbreviated as SS-LUP-332) as a compound capable of activating both PPARγ and PPARδ simultaneously, producing mitochondrial biogenesis rates 3.2 times higher than either receptor activated alone. The question researchers now face: which peptide delivers better outcomes for mitochondrial function, metabolic flexibility, and energy regulation?
- Our team at Real Peptides has synthesised both compounds through small-batch production with verified amino-acid sequencing, and we've observed how research teams apply each one based on experimental design. The gap between choosing MOTS-c and choosing SLU-PP-332 comes down to three factors most peptide comparisons never mention: receptor specificity, endogenous versus synthetic action, and metabolic endpoint.
- What makes MOTS-c vs SLU-PP-332 which better comparison different from other mitochondrial peptide evaluations?
- MOTS-c vs SLU-PP-332 which better comparison depends on research focus: MOTS-c is a mitochondrial-derived peptide encoded in the mitochondrial genome that activates AMPK to modulate existing metabolic pathways, while SLU-PP-332 is a synthetic dual PPAR agonist that forces metabolic reprogramming through simultaneous PPARγ and PPARδ activation. MOTS-c works within the body's existing metabolic framework; SLU-PP-332 creates new metabolic conditions.
- The fundamental difference isn't potency—it's mechanism. MOTS-c mimics a naturally occurring mitochondrial signal; SLU-PP-332 bypasses natural signalling entirely to activate nuclear receptors that wouldn't normally fire together. One enhances what the body already does; the other creates metabolic states the body doesn't produce on its own. This piece covers the specific receptor pathways each compound targets, the metabolic endpoints where they diverge, and the experimental designs where one outperforms the other consistently.